Troy Edward Wilson Purchases 100,000 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) CEO Troy Edward Wilson acquired 100,000 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was purchased at an average price of $12.39 per share, for a total transaction of $1,239,000.00. Following the completion of the transaction, the chief executive officer owned 479,194 shares in the company, valued at $5,937,213.66. The trade was a 26.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Troy Edward Wilson also recently made the following trade(s):

• On Monday, August 17th, Troy Edward Wilson acquired 100,000 shares of Kura Oncology stock. The shares were purchased at an average price of $11.12 per share, with a total value of $1,112,000.00.

Kura Oncology Stock Up 9.6%

KURA stock opened at $13.59 on Wednesday. Kura Oncology, Inc. has a one year low of $7.36 and a one year high of $13.90. The stock has a market capitalization of $1.21 billion, a PE ratio of -4.03 and a beta of 0.38. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. The company has a fifty day moving average of $10.67 and a 200-day moving average of $9.54.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The business had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million. As a group, analysts expect that Kura Oncology, Inc. will post -3.23 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. IFP Advisors Inc lifted its position in shares of Kura Oncology by 115.3% during the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after acquiring an additional 1,284 shares during the period. Allworth Financial LP boosted its stake in shares of Kura Oncology by 59.9% during the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after acquiring an additional 1,553 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Kura Oncology by 49.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock worth $60,000 after acquiring an additional 1,888 shares during the period. Insigneo Advisory Services LLC acquired a new stake in shares of Kura Oncology in the 4th quarter worth approximately $105,000. Finally, LPL Financial LLC purchased a new position in Kura Oncology in the 4th quarter valued at approximately $105,000.

Analysts Set New Price Targets

KURA has been the subject of a number of analyst reports. Morgan Stanley set a $24.00 target price on Kura Oncology in a research note on Monday. Wells Fargo & Company set a $24.00 price target on Kura Oncology in a research note on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Friday, July 17th. Oppenheimer set a $24.00 price objective on Kura Oncology in a report on Thursday, May 28th. Finally, Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research report on Monday. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and an average target price of $25.40.

Kura Oncology News Roundup

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: CEO makes sizable purchase: Chief Executive Officer Troy Edward Wilson bought 100,000 shares for approximately $1.24 million at an average price of $12.39. The purchase increased his direct stake by 26.37%, a potentially confidence-building signal for investors. SEC insider purchase filing
• Positive Sentiment: Analyst remains bullish: Citizens JMP reaffirmed a “Market Outperform” rating and set a $24 price target. That target implies substantial upside from the referenced trading level. Overall, analysts tracked in the report assign KURA a “Moderate Buy” consensus rating with an average target of $25.40. Benzinga analyst rating report
• Positive Sentiment: Institutional accumulation: California State Teachers’ Retirement System increased its position by 968% during the second quarter, while several other institutions initiated or expanded holdings. This may be supporting investor sentiment toward the clinical-stage oncology company.
• Neutral Sentiment: Short-interest data is inconclusive: The report lists short interest at zero shares on both August 10 and August 25, alongside an invalid “NaN” change. Consequently, it does not provide a reliable signal about short-covering or bearish positioning.
• Negative Sentiment: Insider sale disclosed: Insider Brian Powl sold 4,345 shares for approximately $51,662 at an average price of $11.89, reducing his holdings by 2.5%. The sale is relatively small compared with the CEO’s purchase but could temper the positive insider-trading signal. KURA insider sale report

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.